Villoslada, Pablo
Masso, Mar
Paris, Stephane
Hutchings, Simon
Koch, Annelize
Funding for this research was provided by:
Accure Therapeutics Sl (001)
Article History
Received: 30 December 2022
Accepted: 25 March 2023
First Online: 29 March 2023
Competing interests
: PV holds a patent covering the composition of matter and uses of BN201. PV is a founder, holds stocks in Bionure SL, which has licensed the patent rights to Oculis SL and serves on its scientific advisory board, having been compensated by such activities. MM and SP were employees of Accure Therapeutics (formerly Bionure SL), and SH and AK were employees of Simbec-Orion.